JP2008504303A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504303A5 JP2008504303A5 JP2007518381A JP2007518381A JP2008504303A5 JP 2008504303 A5 JP2008504303 A5 JP 2008504303A5 JP 2007518381 A JP2007518381 A JP 2007518381A JP 2007518381 A JP2007518381 A JP 2007518381A JP 2008504303 A5 JP2008504303 A5 JP 2008504303A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- aryl
- heteroalkyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000004404 heteroalkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000027496 Behcet disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000005141 Otitis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000019258 ear infection Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- JSNHAPMMZFHELI-RGMNGODLSA-N CCN([C@@H](C)C1)N=C1[Re] Chemical compound CCN([C@@H](C)C1)N=C1[Re] JSNHAPMMZFHELI-RGMNGODLSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58382204P | 2004-06-28 | 2004-06-28 | |
| PCT/US2005/023274 WO2006004924A2 (en) | 2004-06-28 | 2005-06-28 | Imidazolo-related compounds, compositions and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504303A JP2008504303A (ja) | 2008-02-14 |
| JP2008504303A5 true JP2008504303A5 (enExample) | 2008-08-14 |
Family
ID=35448409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518381A Pending JP2008504303A (ja) | 2004-06-28 | 2005-06-28 | イミダゾロ関連化合物、組成物、及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7271271B2 (enExample) |
| EP (1) | EP1781638A2 (enExample) |
| JP (1) | JP2008504303A (enExample) |
| AU (1) | AU2005260629A1 (enExample) |
| CA (1) | CA2572316A1 (enExample) |
| MX (1) | MX2007000046A (enExample) |
| WO (1) | WO2006004924A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| TW200714610A (en) * | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
| JP2008546843A (ja) * | 2005-06-27 | 2008-12-25 | アムゲン インコーポレイティッド | 抗炎症性アリールニトリル化合物 |
| GB0522130D0 (en) * | 2005-10-31 | 2005-12-07 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US20090170917A1 (en) * | 2007-12-03 | 2009-07-02 | Seung-Yub Lee | Acid Mimic Compounds for the Inhibition of Isoprenyl-S-Cysteinyl Methyltransferase |
| US8252832B2 (en) | 2007-12-14 | 2012-08-28 | Novartis Ag | Kinesin inhibitors as cancer therapeutics |
| WO2009094168A1 (en) * | 2008-01-22 | 2009-07-30 | Amgen Inc. | Cxcr3 antagonists |
| EP2601950A1 (en) | 2011-12-06 | 2013-06-12 | Sanofi | Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists |
| EP2666769A1 (en) | 2012-05-23 | 2013-11-27 | Sanofi | Substituted B-amino acid derivatives as CXCR3 receptor antagonist |
| TWI696615B (zh) | 2016-05-05 | 2020-06-21 | 瑞士商伊蘭科動物健康公司 | 雜芳基-1,2,4-三唑及雜芳基-三唑化合物 |
| CN112341451B (zh) * | 2019-08-09 | 2022-06-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| US20240254121A1 (en) | 2021-05-06 | 2024-08-01 | Bayer Aktiengesellschaft | Alkylamide substituted, annulated imidazoles and use thereof as insecticides |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| US5719144A (en) | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
| WO1998027108A2 (en) | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
| FR2778662B1 (fr) | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1165517A1 (en) | 1999-04-02 | 2002-01-02 | Neurogen Corporation | N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators |
| JP2002541151A (ja) * | 1999-04-02 | 2002-12-03 | ニューロゲン コーポレイション | アリールおよびヘテロアリール縮合アミノアルキル−イミダゾール誘導体：ＧＡＢＡａ受容体の選択的修飾物質 |
| US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
| US6281237B1 (en) * | 1999-04-02 | 2001-08-28 | Neurogen Corporation | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives |
| JP4831906B2 (ja) | 1999-08-27 | 2011-12-07 | ケモセントリックス， インコーポレイテッド | Ｃｘｃｒ３機能を調節するための複素環式化合物および方法 |
| ATE286033T1 (de) | 1999-09-16 | 2005-01-15 | Curis Inc | Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen |
| ES2263501T3 (es) | 1999-10-27 | 2006-12-16 | Cytokinetics, Inc. | Procedimiento y composiciones que utilizan quinazolinonas. |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US7041675B2 (en) | 2000-02-01 | 2006-05-09 | Abbott Gmbh & Co. Kg | Heterocyclic compounds and their use as PARP inhibitors |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| CA2424222A1 (en) | 2000-10-02 | 2002-04-11 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| CA2425185A1 (en) * | 2000-10-06 | 2002-04-11 | Stephane De Lombaert | Benzimidazole and indole derivatives as crf receptor modulators |
| HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| TW200302225A (en) * | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
| EP1521746B1 (en) | 2002-03-07 | 2011-04-27 | X-Ceptor Therapeutics, Inc. | Quinazolinone modulators of nuclear receptors |
| IL164263A0 (en) * | 2002-04-12 | 2005-12-18 | Pfizer | Use of ep4 receptor ligands on the treatment of il-6 involved diseases |
| EP1503993A4 (en) | 2002-05-09 | 2006-05-03 | Cytokinetics Inc | COMPOUNDS, METHODS AND COMPOSITIONS |
-
2005
- 2005-06-27 US US11/168,193 patent/US7271271B2/en not_active Expired - Fee Related
- 2005-06-28 JP JP2007518381A patent/JP2008504303A/ja active Pending
- 2005-06-28 WO PCT/US2005/023274 patent/WO2006004924A2/en not_active Ceased
- 2005-06-28 EP EP05768336A patent/EP1781638A2/en not_active Withdrawn
- 2005-06-28 AU AU2005260629A patent/AU2005260629A1/en not_active Abandoned
- 2005-06-28 MX MX2007000046A patent/MX2007000046A/es active IP Right Grant
- 2005-06-28 CA CA002572316A patent/CA2572316A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504301A5 (enExample) | ||
| JP2008504304A5 (enExample) | ||
| JP2017511357A5 (enExample) | ||
| CA2648036C (en) | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor | |
| JP2004535447A5 (enExample) | ||
| JP2014510727A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| JP2007524696A5 (enExample) | ||
| JP2015502387A5 (enExample) | ||
| JP2021532109A5 (enExample) | ||
| JP2013504593A5 (enExample) | ||
| JP2013534245A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JP2015503622A5 (enExample) | ||
| JP2010511721A5 (enExample) | ||
| CA2402092A1 (en) | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases | |
| JP2011037841A5 (enExample) | ||
| JP2009511490A5 (enExample) | ||
| JP2013523803A5 (enExample) | ||
| JP2010502675A5 (enExample) | ||
| JP2009516727A5 (enExample) | ||
| JP2024505571A5 (enExample) | ||
| JP2014524441A5 (enExample) | ||
| JP2010540593A5 (enExample) | ||
| JP2023164918A5 (enExample) |